<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101278296</journal-id>
<journal-id journal-id-type="pubmed-jr-id">36311</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Rev Clin Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Expert Rev Clin Pharmacol</journal-id>
<journal-title-group>
<journal-title>Expert review of clinical pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1751-2433</issn>
<issn pub-type="epub">1751-2441</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28786716</article-id>
<article-id pub-id-type="pmc">6168071</article-id>
<article-id pub-id-type="doi">10.1080/17512433.2017.1362979</article-id>
<article-id pub-id-type="manuscript">NIHMS1500805</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Adedeji</surname>
<given-names>Waheed Adeola</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Igbinoba</surname>
<given-names>Sharon Iyobor</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fakeye</surname>
<given-names>Titilayo O</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oladosu</surname>
<given-names>Ibrahim Adebayo</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fehintola</surname>
<given-names>Fatai Adewale</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Qing</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morse</surname>
<given-names>Gene D.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Clinical Pharmacology, University College Hospital, Ibadan, Nigeria</aff>
<aff id="A2"><label>2</label>Department of Clinical Pharmacy &amp; Pharmacy Administration, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria</aff>
<aff id="A3"><label>3</label>Department of Clinical Pharmacy &amp; Pharmacy Administration, University of Ibadan, Ibadan, Nigeria</aff>
<aff id="A4"><label>4</label>Department of Chemistry, University of Ibadan, Ibadan, Nigeria</aff>
<aff id="A5"><label>5</label>Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria</aff>
<aff id="A6"><label>6</label>Translational Pharmacology Research Core, School of Pharmacy and Pharmaceutical Sciences, New York Center of Excellence in Bioinformatics and Life Sciences</aff>
<aff id="A7"><label>7</label>Center for Integrated Global Biomedical Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, New York 14203, USA</aff>
<author-notes>
<fn id="FN1">
<p id="P1"><email>fentolamine@yahoo.com</email>, Tel: +2348064251270, <email>qingma@buffalo.edu</email>, Tel: +1-716-881-7500</p>
</fn>
<fn fn-type="COI-statement" id="FN2">
<p id="P34">Declaration of Interest</p>
<p id="P35">Q Ma is currently supported in part by NIH K08MH098794. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>9</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>02</day>
<month>10</month>
<year>2018</year>
</pub-date>
<volume>10</volume>
<issue>10</issue>
<fpage>1145</fpage>
<lpage>1152</lpage>
<!--elocation-id from pubmed: 10.1080/17512433.2017.1362979-->
<abstract id="ABS1">
<sec id="S1">
<title>Background:</title>
<p id="P2">There is a lack of information on CYP2D6, a major metabolizing enzyme, in Africa ethnic nationalities. The objective was to determine CYP2D6 phenotype in Yoruba Nigerians using dextromethorphan (DEX).</p>
</sec>
<sec id="S2">
<title>Method:</title>
<p id="P3">A total of 89 healthy volunteers received 30 mg of DEX orally followed by blood and urine sample collection at 3-hour and over 8 hours post-dose, respectively. DEX and dextrorphan (DOR) concentrations were determined using High Performance Liquid Chromatography (HPLC). The metabolic ratio (MR, DEX/DOR) were plotted for the phenotype determination.</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P4">The log MR that separated poor (PMs) from normal metabolizers (NMs) was 0.28 and 0.75 for urine and plasma, respectively. Two subjects (2.3%) identified as PMs had a mean MR of 17 and 3.2 in plasma and urine, significantly higher than that of NMs (p&lt;0.0001). A positive correlation between urine and plasma MR was noted.</p>
</sec>
<sec id="S4">
<title>Conclusion:</title>
<p id="P5">The prevalence of PMs in the Yoruba Nigerians was similar to that reported among blacks.</p>
</sec>
</abstract>
<kwd-group>
<kwd>CYP2D6</kwd>
<kwd>dextromethorphan</kwd>
<kwd>metabolic ratio</kwd>
<kwd>phenotyping</kwd>
<kwd>Yoruba Nigerian</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>